human epidermal growth factor
oligopeptide-1, sh-oligopeptide-1, nepidermin (INN), EGF, rhEGF, recombinant human epidermal growth factor, beta-urogastrone
Oligopeptide-1 is the cosmetic name for human epidermal growth factor, a 53-residue protein with three disulfide bonds, a genuine growth factor, not a designed cosmetic peptide. Its international nonproprietary name is nepidermin. It is a licensed wound-healing medicine in several countries with real randomised trial evidence in diabetic foot ulcers, and separately an unregulated cosmetic ingredient with much thinner anti-ageing evidence. Those two evidence bases should not be conflated.
Mechanism
EGF binds the epidermal growth factor receptor (EGFR, also called ErbB1 or HER1), a receptor tyrosine kinase. Ligand binding drives receptor dimerisation and trans-autophosphorylation of cytoplasmic tyrosines, which recruit adaptors and activate the RAS-RAF-MEK-ERK cascade, the PI3K-AKT pathway and phospholipase C gamma. In skin the downstream consequence is keratinocyte proliferation and directed migration, which is why EGF matters for re-epithelialisation of wounds. EGFR signalling is not incidental to skin: Rittié and colleagues showed that retinoid-induced epidermal hyperplasia is itself mediated by EGFR activation through specific induction of its ligands heparin-binding EGF and amphiregulin in human skin in vivo, and the severe acneiform eruptions caused by systemic EGFR inhibitors in oncology are direct clinical evidence of how much epidermal homeostasis depends on this receptor.
For cosmetic use, the limiting factor is delivery. A 6 kDa, disulfide-bonded, hydrophilic protein does not cross an intact stratum corneum in useful quantity. Every human cosmetic study with a positive result has used an assisted-delivery route: dissolving micro-spicules, hyaluronic acid microneedle patches, fractional radiofrequency microporation, or post-procedure application to laser-resurfaced skin where the barrier is already breached. Applied to intact skin from a conventional serum, there is no published evidence that EGF reaches viable epidermis. There is also a legitimate unresolved question about whether chronically stimulating a proliferative receptor in photodamaged skin carrying pre-existing mutations is prudent; no clinical data demonstrate harm, but no long-term safety study exists either.
What the research shows
On the medical side, Park and colleagues randomised 167 patients at six centres to 0.005% recombinant human EGF spray (n=82) or saline (n=85) twice daily for up to 12 weeks: complete healing occurred in 73.2% versus 50.6% (p=.001), with faster healing velocity and shorter time to complete healing. Meta-analyses by Zhao and colleagues concluded that pooled data favour topical rhEGF for complete healing of diabetic foot ulcers. The Cochrane review by Martí-Carvajal and colleagues covered 11 different growth factors and concluded that growth factors may increase the likelihood of complete healing, but that this rests on trials with high risk of systematic error and that the safety profiles remain unclear, a caveat that should travel with every positive citation in this area.
On the cosmetic side, Ha and colleagues ran a randomised, controlled split-face study in 20 healthy volunteers aged 33 to 54, applying a soluble micro-spicule EGF cream to one side and an EGF-only cream to the other daily for four weeks with eight weeks of follow-up; the micro-spicule side showed significantly greater increases in ultrasonographically measured dermal depth and density at four and eight weeks. Note what this establishes: that the delivery vehicle mattered, not that EGF outperformed placebo. Two co-authors were affiliated with the company producing the micro-spicule technology, and the paper carries a published erratum. An and colleagues tested a cross-linked hyaluronic acid microneedle patch combining acetyl hexapeptide-8 with EGF in Korean subjects, again a delivery device and a combination product. Across the cosmetic literature the pattern is consistent: small samples, short duration, combination products, assisted delivery, and few placebo-controlled designs.
Evidence assessment
Mixed evidence
This tier is a compromise between two very different evidence bases, and the split matters more than the label. For wound healing, specifically diabetic foot ulcers, recombinant human EGF has randomised controlled trial support, including a 167-patient phase III placebo-controlled trial, positive meta-analyses, and approval as a medicine in South Korea, Cuba, China and elsewhere. Against that, the 2015 Cochrane review of growth factors for diabetic foot ulcers judged the evidence low quality with high risk of bias, and EGF holds no FDA or EMA marketing authorisation. For the cosmetic anti-ageing use that puts it in this library, the evidence is a handful of small trials, mostly Korean, mostly using assisted delivery, several without placebo control and none longer than a few months. Averaging a genuinely trial-supported medical indication against a thin cosmetic one gives 'mixed'.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Topical epidermal growth factor spray for the treatment of chronic diabetic foot ulcers: A phase III multicenter, double-blind, randomized, placebo-controlled trial Preclinical only
Complete wound healing in 73.2% with 0.005% rhEGF spray versus 50.6% with placebo (p=.001), with faster healing velocity and shorter time to 50% ulcer size reduction and to complete healing.
Growth factors for treating diabetic foot ulcers Preclinical only
Growth factors may increase the likelihood of complete healing of diabetic foot ulcers, but the conclusion rests on trials with high risk of systematic error; GRADE assessment indicated further trials are needed before firm conclusions can be drawn, and the safety profiles of the growth factors are unclear.
Efficacy and safety of recombinant human epidermal growth factor for diabetic foot ulcers: A systematic review and meta-analysis of randomised controlled trials Preclinical only
Pooled analysis favoured topical rhEGF for complete healing of diabetic foot ulcers.
The Effect of Micro-Spicule Containing Epidermal Growth Factor on Periocular Wrinkles Preclinical only
The micro-spicule EGF side showed statistically significant increases in dermal depth and density versus the EGF-only side at 4 and 8 weeks, with good tolerability and no significant side effects.
Anti-Wrinkle Efficacy of Cross-Linked Hyaluronic Acid-Based Microneedle Patch with Acetyl Hexapeptide-8 and Epidermal Growth Factor on Korean Skin Preclinical only
Reported anti-wrinkle benefit from a microneedle patch delivering EGF together with acetyl hexapeptide-8.
Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligands heparin-binding EGF and amphiregulin in human skin in vivo Preclinical only
Retinoid-driven epidermal thickening depends on EGFR activation via induction of heparin-binding EGF and amphiregulin, establishing how central EGFR signalling is to human epidermal homeostasis.
Safety
As a wound-healing medicine, topical rhEGF has been reasonably well tolerated in trials, with local application-site reactions the commonest complaint; the Cochrane authors noted that growth-factor safety profiles are unclear. Intralesional formulations used in some countries have reported pain, burning and shivering at injection sites. For cosmetic use, reported adverse effects are minimal, but the safety database is short-term. Two considerations deserve stating rather than dismissing. First, EGFR is a proliferative receptor and its inhibition is an established anticancer strategy; whether sustained topical stimulation of EGFR in chronically sun-damaged skin carries long-term risk has not been studied, and absence of evidence of harm is not evidence of absence. Second, application to skin with undiagnosed lesions, or to actinic keratoses, has not been evaluated. EGF cosmetic products are frequently promoted for use immediately after laser resurfacing or microneedling, which is precisely the setting of maximal absorption and minimal safety data. Not evaluated for use in pregnancy or lactation.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Not licensed as a medicine by the MHRA. As a cosmetic ingredient, note that Annex II of the UK Cosmetics Regulation (retained Regulation (EC) No 1223/2009) prohibits cells, tissues and products of human origin in cosmetics, so only recombinant material produced in bacterial or yeast expression systems can lawfully be used; material sourced from human cells or conditioned media is not permitted. Products asserting growth-factor activity risk classification as medicinal by function. |
| United States | Recombinant human EGF holds no FDA marketing authorisation as a drug or biologic. It is used in cosmetics, where the FDA has stated that products claiming to affect the structure or function of the skin may be unapproved new drugs; growth-factor products have been an area of specific regulatory attention. Under the FD&C Act as amended by the Modernization of Cosmetics Regulation Act 2022, cosmetic ingredients other than colour additives are not pre-approved. |
| WADA (sport) | Not named on the WADA Prohibited List. Section S2.2 prohibits specified growth factors, including fibroblast growth factors, hepatocyte growth factor, insulin-like growth factor-1 and its analogues, mechano growth factors, platelet-derived growth factor and vascular endothelial growth factor, together with any other growth factor affecting muscle, tendon or ligament protein synthesis, vascularisation, energy utilisation, regenerative capacity or fibre-type switching. EGF is not named, and topical cosmetic use raises no realistic anti-doping issue, but athletes should be aware of the catch-all wording in that section. |
Questions
It is a protein by any normal definition: 53 amino acids with three internal disulfide bonds, folded into a defined structure, weighing about 6.2 kDa. The INCI name 'oligopeptide-1' understates what it is. It is human epidermal growth factor, whose international nonproprietary name is nepidermin, and the molecule whose discovery earned Stanley Cohen a share of the 1986 Nobel Prize.
Through intact stratum corneum, almost certainly not in useful quantity, and no published study demonstrates that it does. Every positive human cosmetic study has used an assisted route: micro-spicules, microneedle patches, radiofrequency microporation, or application to skin already breached by laser or needling.
Yes. Recombinant human EGF is approved for wound-healing indications, principally diabetic foot ulcers, in several countries including South Korea, Cuba and China, with randomised trial support including a 167-patient phase III placebo-controlled trial. It has no FDA or EMA marketing authorisation and no MHRA licence, and the Cochrane review of growth factors for these ulcers rated the overall evidence as low quality.
No clinical evidence of harm has been reported, but no long-term safety study exists either. EGFR is a proliferative receptor and inhibiting it is an established anticancer strategy, so the question is reasonable rather than alarmist. What can be said honestly is that the safety database for cosmetic EGF is short-term and that its use on skin with undiagnosed lesions has not been studied.
Yes. The UK Cosmetics Regulation prohibits cells, tissues and products of human origin in cosmetics, so only recombinant EGF produced in bacterial or yeast systems can lawfully be used. Products marketed on the basis of human cell conditioned media are a different and more problematic category.